Filling the Shortage Gap
During periods when brand-name GLP-1 drugs were in short supply, compounding pharmacies began producing versions of semaglutide and tirzepatide, often at substantially lower cost. While compounding serves legitimate medical needs, the scale of GLP-1 compounding raised significant safety concerns, as compounded products do not undergo the same rigorous FDA review for safety, efficacy, and manufacturing quality as approved medications.
The Specific Risks
Documented concerns with compounded GLP-1 products include dosing errors — some sold in vials requiring patients to measure doses themselves, leading to accidental overdoses — variability in purity and concentration, use of different salt forms with uncertain equivalence, and inconsistent sterility. Regulators have received reports of adverse events. Because these products bypass standardized manufacturing, the patient bears more risk, and the cost savings may come at the expense of safety assurance.
Making Informed Decisions
Patients considering compounded alternatives should understand the regulatory differences, verify that any compounding pharmacy is reputable and licensed, and be especially cautious about products requiring self-measurement of doses. As shortages ease and brand availability improves, the case for compounded versions weakens. Medical supervision remains essential regardless of source. Facilities can source pharmacy supplies and patient care supplies from our catalog.
